 Home > Medical News > Latest Medical News > Junshi VV116 Phase III Clinical Treatment for Moderate and Severe COVID-19 Patients Completed the First Patient Dosing

Junshi VV116 Phase III Clinical Treatment for Moderate and Severe COVID-19 Patients Completed the First Patient Dosing

 Last Update: 2022-05-27
 Source: Internet
 Author: User

Tags

flake drug

chantix drug interactions

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 16, Junshi Biology announced that the oral nucleoside anti-SARS-CoV2 drug VV116 tablets jointly developed by the company's holding subsidiary Juntuo Biotechnology and Wangshan Wangshui has recently launched a study on the treatment of moderate to severe new coronaviruses.

VV116 is a novel oral nucleoside anti-SARS-CoV-2 drug that inhibits SARS-CoV-2 replication

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.